Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine
Article
[키워드] ACM
acute respiratory syndrome
adverse effect
airway
antibodies
antibody
antigen presenting cells
artificial
Beta
Beta spike
C57BL/6
cell membrane
clinical symptom
clinical trial
component
conditions
coronavirus
coronavirus disease
COVID-19
CpG
cross-neutralizing
current
delivery of cargo
dendritic cells
dose
doses
evaluate
evaluated
Formulation
generate
Generation
Good
hamster
hamsters
immune responses
immunization
immunogenic
induce
Infection
initiated
interval
intranasal
mice
neutralize
neutralizing antibody
neutralizing responses
New
omicron
Phase 1
polymersome
Practice
PROTECT
reduction
repeated
Safety
SARS-CoV-2
second
serum IgG
spike
Spike protein
Spike-based vaccine
Support
Toxicity
upper respiratory tract
Vaccine
variants
viral clearance
Viral load
virus
weight loss
wild type
[DOI] 10.1021/acsnano.2c06350 PMC 바로가기
[DOI] 10.1021/acsnano.2c06350 PMC 바로가기